← Leaderboards
Stephen A Spector
University Of California San Diego
$452,436
Attributed
$452,436
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$452,436 · 7
By mechanism
P30$281,143 · 1
P50$171,293 · 1
M01$0 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Richard Haubrich$0
- Teresa Dianne Langford$10,314,213
- Douglas D Richman$67,820,652
- William Fenical$13,401,375
- Richard Syd Kornbluth$3,601,719
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectHiv InfectionsAids TherapyZidovudineInfant Human (0-1 Year)Pediatric AidsMicroorganism Disease ChemotherapyDrug Screening /EvaluationDosageAntiviral AgentsCytomegalovirusCombination ChemotherapyClinical Trial Phase IProtease InhibitorVirus ReplicationHuman Immunodeficiency Virus 1LamivudineNevirapineCongenital DisordersHelper T LymphocyteCombination Cancer TherapyClinical Trials
Grant awards (47)
COMPARISON OF COMBINATIONS OF PI, NRTI, AND NNRTI$0
M01 · FY2002 · RR
COMPARISON OF COMBINATIONS OF PI, NRTI, AND NNRTI$0
M01 · FY2002 · RR
ACTG382--I592089 WITH STANDARD ZIDOVUDINE THERAPY IN NEONATES$0
M01 · FY2002 · RR
EVALUATION OF GANCICLOVIR FOR CONGENITAL CYTOMEGALOVIRUS$0
M01 · FY2002 · RR
EVALUATION OF GANCICLOVIR FOR CONGENITAL CYTOMEGALOVIRUS$0
M01 · FY2002 · RR
EVALUATION OF GANCICLOVIR FOR CONGENITAL CYTOMEGALOVIRUS$0
M01 · FY2002 · RR
EVALUATION OF GANCICLOVIR FOR CONGENITAL CYTOMEGALOVIRUS$0
M01 · FY2002 · RR
ACTG382--I592089 WITH STANDARD ZIDOVUDINE THERAPY IN NEONATES$0
M01 · FY2002 · RR
ACTG382--I592089 WITH STANDARD ZIDOVUDINE THERAPY IN NEONATES$0
M01 · FY2002 · RR
ACTG382--I592089 WITH STANDARD ZIDOVUDINE THERAPY IN NEONATES$0
M01 · FY2002 · RR
ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 IN HIV INFECTION$0
M01 · FY2002 · RR
ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 IN HIV INFECTION$0
M01 · FY2002 · RR
ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 IN HIV INFECTION$0
M01 · FY2002 · RR
ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 IN HIV INFECTION$0
M01 · FY2002 · RR
COMPARISON OF COMBINATIONS OF PI, NRTI, AND NNRTI$0
M01 · FY2002 · RR
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS AND CHILDREN$0
M01 · FY2002 · RR
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS AND CHILDREN$0
M01 · FY2002 · RR
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS AND CHILDREN$0
M01 · FY2002 · RR
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS AND CHILDREN$0
M01 · FY2002 · RR
COMPARISON OF COMBINATIONS OF PI, NRTI, AND NNRTI$0
M01 · FY2002 · RR
CORE--CLINICAL VIROLOGY AND SPECIMEN BANKING$180,480
P30 · FY2001 · AI
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS AND CHILDREN$0
M01 · FY2001 · RR
EVALUATION OF GANCICLOVIR FOR CONGENITAL CYTOMEGALOVIRUS$0
M01 · FY2001 · RR
EVALUATION OF GANCICLOVIR FOR CONGENITAL CYTOMEGALOVIRUS$0
M01 · FY2001 · RR
ACTG382--I592089 WITH STANDARD ZIDOVUDINE THERAPY IN NEONATES$0
M01 · FY2001 · RR
ACTG382--I592089 WITH STANDARD ZIDOVUDINE THERAPY IN NEONATES$0
M01 · FY2001 · RR
ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 IN HIV INFECTION$0
M01 · FY2001 · RR
ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 IN HIV INFECTION$0
M01 · FY2001 · RR
COMPARISON OF COMBINATIONS OF PI, NRTI, AND NNRTI$0
M01 · FY2001 · RR
COMPARISON OF COMBINATIONS OF PI, NRTI, AND NNRTI$0
M01 · FY2001 · RR
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS AND CHILDREN$0
M01 · FY2001 · RR
CORE--VIROLOGY$171,293
P50 · FY2000 · MH
CORE--CLINICAL VIROLOGY AND SPECIMEN BANKING$100,663
P30 · FY2000 · AI
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS AND CHILDREN$0
M01 · FY2000 · RR
COMPARISON OF COMBINATIONS OF PI, NRTI, AND NNRTI$0
M01 · FY2000 · RR
COMPARISON OF COMBINATIONS OF PI, NRTI, AND NNRTI$0
M01 · FY2000 · RR
COMPARISON OF COMBINATIONS OF PI, NRTI, AND NNRTI$0
M01 · FY2000 · RR
ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 IN HIV INFECTION$0
M01 · FY2000 · RR
ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 IN HIV INFECTION$0
M01 · FY2000 · RR
EVALUATION OF GANCICLOVIR FOR CONGENITAL CYTOMEGALOVIRUS$0
M01 · FY2000 · RR
ACTG382--I592089 WITH STANDARD ZIDOVUDINE THERAPY IN NEONATES$0
M01 · FY2000 · RR
ACTG382--I592089 WITH STANDARD ZIDOVUDINE THERAPY IN NEONATES$0
M01 · FY2000 · RR
ACTG382--I592089 WITH STANDARD ZIDOVUDINE THERAPY IN NEONATES$0
M01 · FY2000 · RR
EVALUATION OF GANCICLOVIR FOR CONGENITAL CYTOMEGALOVIRUS$0
M01 · FY2000 · RR
EVALUATION OF GANCICLOVIR FOR CONGENITAL CYTOMEGALOVIRUS$0
M01 · FY2000 · RR
ZDV &3TC &NEVIRAPINE &ZDV &3TC &NEVIRAPINE &1592U89 IN HIV INFECTION$0
M01 · FY2000 · RR
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS AND CHILDREN$0
M01 · FY2000 · RR